Biotron Limited
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited (BITRF) - Net Assets
Latest net assets as of December 2025: $2.70 Million USD
Based on the latest financial reports, Biotron Limited (BITRF) has net assets worth $2.70 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.86 Million) and total liabilities ($1.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.70 Million |
| % of Total Assets | 69.92% |
| Annual Growth Rate | -11.4% |
| 5-Year Change | -85.71% |
| 10-Year Change | -82.41% |
| Growth Volatility | 112.41 |
Biotron Limited - Net Assets Trend (2001–2025)
This chart illustrates how Biotron Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biotron Limited (2001–2025)
The table below shows the annual net assets of Biotron Limited from 2001 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $551.89K | +326.16% |
| 2024-06-30 | $-244.03K | -107.69% |
| 2023-06-30 | $3.17 Million | +190.40% |
| 2022-06-30 | $1.09 Million | -71.72% |
| 2021-06-30 | $3.86 Million | -44.60% |
| 2020-06-30 | $6.97 Million | +28.20% |
| 2019-06-30 | $5.44 Million | +324.42% |
| 2018-06-30 | $1.28 Million | -11.01% |
| 2017-06-30 | $1.44 Million | -54.09% |
| 2016-06-30 | $3.14 Million | -24.28% |
| 2015-06-30 | $4.14 Million | +198.21% |
| 2014-06-30 | $1.39 Million | -68.96% |
| 2013-06-30 | $4.48 Million | -45.88% |
| 2012-06-30 | $8.27 Million | +244.52% |
| 2011-06-30 | $2.40 Million | +39.75% |
| 2010-06-30 | $1.72 Million | +104.11% |
| 2009-06-30 | $841.51K | -54.35% |
| 2008-06-30 | $1.84 Million | +35.94% |
| 2007-06-30 | $1.36 Million | -69.84% |
| 2006-06-30 | $4.50 Million | +97.30% |
| 2005-06-30 | $2.28 Million | -22.91% |
| 2004-06-30 | $2.96 Million | -48.69% |
| 2003-06-30 | $5.76 Million | -32.14% |
| 2002-06-30 | $8.49 Million | -15.78% |
| 2001-06-30 | $10.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biotron Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5863083200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $59.32 Million | 10749.28% |
| Total Equity | $551.89K | 100.00% |
Biotron Limited Competitors by Market Cap
The table below lists competitors of Biotron Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bioscience Animal Health PCL
BK:BIS
|
$4.82 Million |
|
Refined Metals Corp.
PINK:RFMCF
|
$4.82 Million |
|
WiSA Technologies Inc
NASDAQ:WISA
|
$4.82 Million |
|
Finlay Minerals Ltd
OTCQB:FYMNF
|
$4.82 Million |
|
Binect AG
XETRA:MA10
|
$4.82 Million |
|
SE-Education Public Company Limited
BK:SE-ED
|
$4.82 Million |
|
Evolva Holding SA
PINK:ELVAF
|
$4.82 Million |
|
Scandium Canada Ltd
PINK:SCDCF
|
$4.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biotron Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -244,032 to 551,895, a change of 795,927.
- Net loss of 318,572 reduced equity.
- Other factors increased equity by 1,114,499.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-318.57K | -57.72% |
| Other Changes | $1.11 Million | +201.94% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Biotron Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.89x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 4.89x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-06-30 | $0.57 | $0.00 | x |
| 2001-06-30 | $0.15 | $0.00 | x |
| 2002-06-30 | $0.10 | $0.00 | x |
| 2003-06-30 | $0.07 | $0.00 | x |
| 2004-06-30 | $0.03 | $0.00 | x |
| 2005-06-30 | $0.03 | $0.00 | x |
| 2006-06-30 | $0.05 | $0.00 | x |
| 2007-06-30 | $0.01 | $0.00 | x |
| 2008-06-30 | $0.02 | $0.00 | x |
| 2009-06-30 | $0.01 | $0.00 | x |
| 2010-06-30 | $0.01 | $0.00 | x |
| 2011-06-30 | $0.01 | $0.00 | x |
| 2012-06-30 | $0.03 | $0.00 | x |
| 2013-06-30 | $0.02 | $0.00 | x |
| 2014-06-30 | $0.00 | $0.00 | x |
| 2015-06-30 | $0.01 | $0.00 | x |
| 2016-06-30 | $0.01 | $0.00 | x |
| 2017-06-30 | $0.00 | $0.00 | x |
| 2018-06-30 | $0.00 | $0.00 | x |
| 2019-06-30 | $0.01 | $0.00 | x |
| 2020-06-30 | $0.01 | $0.00 | x |
| 2021-06-30 | $0.01 | $0.00 | x |
| 2022-06-30 | $0.00 | $0.00 | x |
| 2023-06-30 | $0.00 | $0.00 | x |
| 2024-06-30 | $0.00 | $0.00 | x |
| 2025-06-30 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biotron Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -57.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.57%
- • Asset Turnover: 1.85x
- • Equity Multiplier: 1.78x
- Recent ROE (-57.72%) is above the historical average (-98.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -12.70% | -9800.92% | 0.00x | 1.01x | $-2.29 Million |
| 2002 | -19.64% | -2657.00% | 0.01x | 1.02x | $-2.52 Million |
| 2003 | -47.36% | 0.00% | 0.00x | 1.03x | $-3.30 Million |
| 2005 | -82.66% | 0.00% | 0.00x | 1.07x | $-2.11 Million |
| 2006 | -48.91% | -276.65% | 0.17x | 1.07x | $-2.65 Million |
| 2007 | -238.49% | -803.57% | 0.26x | 1.12x | $-3.37 Million |
| 2008 | -102.10% | 0.00% | 0.00x | 1.23x | $-2.07 Million |
| 2009 | -211.06% | 0.00% | 0.00x | 1.26x | $-1.86 Million |
| 2010 | -109.01% | 0.00% | 0.00x | 1.08x | $-2.04 Million |
| 2011 | -79.47% | 0.00% | 0.00x | 1.10x | $-2.15 Million |
| 2012 | -28.76% | 0.00% | 0.00x | 1.02x | $-3.21 Million |
| 2013 | -86.05% | -431.72% | 0.18x | 1.09x | $-4.30 Million |
| 2014 | -222.11% | -179.15% | 0.92x | 1.34x | $-3.22 Million |
| 2015 | -65.73% | -162.85% | 0.36x | 1.11x | $-3.14 Million |
| 2016 | -95.77% | -194.05% | 0.44x | 1.11x | $-3.32 Million |
| 2017 | -214.80% | -186.41% | 0.81x | 1.43x | $-3.24 Million |
| 2018 | -124.36% | -171175.62% | 0.00x | 1.26x | $-1.72 Million |
| 2019 | -29.63% | -150.24% | 0.18x | 1.08x | $-2.16 Million |
| 2020 | -51.28% | -7151.92% | 0.01x | 1.12x | $-4.27 Million |
| 2021 | -82.69% | -218.50% | 0.34x | 1.12x | $-3.58 Million |
| 2022 | -254.56% | -178.44% | 0.82x | 1.74x | $-2.89 Million |
| 2023 | -110.09% | -244.03% | 0.35x | 1.30x | $-3.81 Million |
| 2024 | 0.00% | -208.89% | 3.33x | 0.00x | $-3.41 Million |
| 2025 | -57.72% | -17.57% | 1.85x | 1.78x | $-373.76K |
Industry Comparison
This section compares Biotron Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biotron Limited (BITRF) | $2.70 Million | -12.70% | 0.43x | $4.82 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |